echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Fuchs: U.S. to advance Phase 3 clinical trials of three new crown candidate vaccines

    Fuchs: U.S. to advance Phase 3 clinical trials of three new crown candidate vaccines

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    In an interview with U.Smedia, Fauci said the mRNA-1273 vaccine developed by Modner will be the first to begin phase III clinical trials in July; a vaccine developed by Astra-Jelikon and Oxford University in the U.Kwill begin Phase III clinical trials in August; and Johnson and Johnson's new crown vaccine will begin phase III clinical trials in SeptemberMr Fauci said the clinical trial plan for the vaccine was in sync with his previously anticipated schedule, with large-scale applications of the new crown vaccine waiting until the end of the year or early next yearEach of the three clinical trials will be conducted in more than 50 locations, most of them in the United States, where 30,000 people will participate, CNN reportedRobert Scully, head of the Department of Infectious Diseases at the University of California, San Diego, told Xinhua that it is relatively easy for candidate vaccines to enter phase I clinical trials and needs to meet conditions that enable the immune system to recognize virusesAfter evaluating the safety of the candidate vaccine and its induced immune response in Phase I and II clinical trials, the effective vaccine will enter the larger Phase III clinical trialPhase III clinical trials require a larger sample size, mainly to assess the effectiveness of vaccines in reducing infection rates and so onIn mid-May, U.SPresident Donald Trump announced a program called Operation Quds to accelerate research into new vaccines, drugs and testing, and said he expects to develop a new vaccine by the end of the year.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.